The apoptotic effect of Rituxan on Ramos cells
| Treatment . | Apoptosis (%)* . | Necrosis (%)† . |
|---|---|---|
| Control | 3.5 ± 2.5 | 5.0 ± 2.3 |
| Rituxan monomer | 6.2 ± 1.5 | 6.0 ± 2.2 |
| Rituxan monomer + GAMIg | 32.2 ± 6.8 | 9.5 ± 0.7 |
| Rituxan homodimer | 33.5 ± 3.9 | 8.2 ± 0.3 |
| GAHIgM | 33.7 ± 7.8 | 9.6 ± 3.2 |
| NaN3 | 85.4 ± 6.4 | 10.4 ± 5.6 |
| Treatment . | Apoptosis (%)* . | Necrosis (%)† . |
|---|---|---|
| Control | 3.5 ± 2.5 | 5.0 ± 2.3 |
| Rituxan monomer | 6.2 ± 1.5 | 6.0 ± 2.2 |
| Rituxan monomer + GAMIg | 32.2 ± 6.8 | 9.5 ± 0.7 |
| Rituxan homodimer | 33.5 ± 3.9 | 8.2 ± 0.3 |
| GAHIgM | 33.7 ± 7.8 | 9.6 ± 3.2 |
| NaN3 | 85.4 ± 6.4 | 10.4 ± 5.6 |
Cells (2 × 105/mL) were incubated overnight at 37°C with Rituxan monomer (10 μg/mL) alone or cross-linked by 50 μg/mL GAMIg, Rituxan homodimers (10 μg/mL), GAMIgM (20 μg/mL), or NaN3 (5 mg/mL), and then evaluated in the annexin V assay.
GAMIg indicates goat antimouse immunoglobulin; GAHIg, goat antihuman immunoglobulin M.
As determined by means of the Annexin V staining assay in 3 to 5 experiments.
As determined by propidium iodide staining in 3 to 5 experiments.